Physician profile
Maynard C Buszek
NPI 1003990037
$601.32
in general payments reported to CMS, 2019-2025
16 companies · $94.17 in 2025
The $94.17 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $16.76 · 2021: $18.13 · 2022: $127 · 2023: $186 · 2024: $32.66 · 2025: $94.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $103.80 | 2023-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $59.56 | 2020-2023 | Ongentys, Ingrezza |
| Catalyst Pharmaceuticals, INC. | $52.97 | 2022-2023 | Firdapse |
| Abbvie INC. | $48.95 | 2023 | Botox |
| Avanir Pharmaceuticals, INC. | $42.86 | 2019 | |
| Biogen, INC. | $34.79 | 2019 | |
| Amneal Pharmaceuticals LLC | $34.72 | 2019-2023 | Rytary |
| Astrazeneca Pharmaceuticals Lp | $30.82 | 2025 | Wainua |
| Genzyme Corporation | $28.97 | 2019-2023 | |
| Avion Pharmaceuticals | $28.84 | 2022 | |
| Genentech USA, INC. | $28.70 | 2025 | Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $25.12 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.29 | 2019 | |
| Neurelis, INC. | $19.43 | 2022 | |
| Csl Behring | $19.37 | 2023 | Hizentra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $18.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maynard Buszek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.